Featured Trends
We’ve sliced and diced our portfolio into distinct “trends” that define our edge.
Climate 100
We are pleased to report that as of April 2021 the SOSV Climate Tech 100 have raised $1.85 billion from investors and have a market cap of $5.65 billion. The average company is four years old. SOSV (our parent fund) has invested $89 million in these companies and was in most cases the first investor, though we continued investing through early rounds.
IndieBio has never been one to shy away from the riskiest and most impactful investments for our planet. In fact, we embrace them.
Female Founder
Boosting female representation in the startup world is an ongoing challenge, but we’re dedicated to gender balance, not only because it’s the right thing to do, but because we would be dismissing impressive companies otherwise. We’ve found that more gender balance leads to better workplace culture and better ideas being exchanged.
Future of Food
It’s not just that we can make meat and fish in the lab, or with mushrooms and chickpeas. It’s not just that AI can predict the best plant ingredients to make the best tasting milk and yogurt. And it’s not just that yeast can be fermented to produce the healthier and better food preservatives. We’re diving deep every day into the foods that will satisfy novelty-seekers and conventionalists alike.
We’re putting big bets on the newest technologies and trends we think are ahead of the curve.
Future of Medicine
Medicine ain’t what it used to be. Today, bloodletting, skull-drilling and giving children cocaine for toothaches are relics of the past. Tomorrow, so too will addictive opioids, chemotherapy, and psychiatric drugs that are non-selectively bathing our bodies in chemicals.
The future of medicine is an exciting one, and we’re excited to share the most exciting technologies that enable the next wave of medicine and healthcare.
Impact
Our mission has always been Human and Planetary Health from the beginning, so it’s hard to say which of our companies are “impact” companies (in some ways, they all are).
Here, we narrowed down the startups that are directly addressing sustainability issues, improving public health, mitigating inequality, and democratizing access to infrastructure and technologies.
New Frontiers
Raising Now
Every season of the year, a new batch and about one-sixth of our alumni are in raise mode. These companies are currently raising and would love to talk to interested investors. We can set up those meetings or you can contact the companies directly.
Sustainable Solutions
Drug discovery platform to inhibit protein-protein interactions
The only computational drug design platform that models against a moving target
Every year, 2 million people develop corneal blindness, but only about 200,000 undergo a corneal transplantation to regain their vision. Almost 13 million people are on waiting lists for donor tissue, and even if they obtain it, the rejection rate for corneal replacements climbs from 10% in the first two years to almost 50% by […]
Why we invested: The biggest risk in cancer immunotherapy is the safety: the cancer targets (i.e., neoantigens) are not differentiated enough from healthy cells, and can therefore lead to the immune system attacking the patient’s. When we met Dr. Corey Dambacher (the founder of Rybodyn), he said he has been sitting on a treasure trove […]
Why we invested: For all the hype of cell therapies, to get beyond the 5% of eligible patients who receive such therapies today, the market needs 1) higher transfection success, and 2) multi-protein delivery in one construct. The founder of Able sciences are veteran drug developers who invented a self-amplifying RNA that delivers on both […]
Why we invested: Reactosome uses synthetic nuclei as a novel class of gene therapy. This is not a “better” LNP, AAV, etc – This would be peerless in delivering very large DNA payloads ALONG WITH the transcription machinery to transcribe RNAs. As a result, the internalized nuclei can continuously pump out mRNAs into the cytosol. […]
Over 32 million cancer survivors face the risk of recurrence. Patients are told they are “cancer-free” only to discover that a few undetectable cancer cells survived initial treatment and have begun to multiply. FREZENT is developing a novel class of bispecific antibodies for targeting dormant cancer cells that have survived chemotherapy and may cause recurrence. […]
Karma Biotech is an oncology company targeting solid tumors, starting with colorectal cancer. Their technology aims to deliver cytokines and other biologicals, such as IL-15, specifically to tumor and metastatic sites, avoiding the dangers of systemic toxicity. This localized IL-15 will turn cold tumors hot, allowing the body to clear the cancer. The founders at […]
Vascular endothelial Growth factor, also known as VEGF, is primarily responsible for forming and maintaining new blood vessels. Under abnormal conditions, especially in the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy, it causes the formation of abnormal blood vessels, which can bleed, leak, and eventually lead to scar formation and vision loss. […]
A wide number of cancers exhibit misregulated genome packaging at the chromatin level. If chromatin that should be tightly condensed, becomes loosely packed (or vice-versa), the normal brakes on cell growth aren’t operant, leading to uncontrolled cell growth. Being able to regulate and control the chromatin state has been a high-value target for oncology. Coming […]